Royalty Pharma(RPRX) ZACKS·2025-05-08 15:30Core Insights - Royalty Pharma reported revenue of $839 million for the quarter ended March 2025, reflecting a 17% increase year-over-year and surpassing the Zacks Consensus Estimate of $793.58 million by 5.72% [1] - The company's EPS for the quarter was $1.06, up from $0.98 in the same quarter last year, also exceeding the consensus EPS estimate of $0.99 by 7.07% [1] Revenue Performance - The total portfolio receipts from royalty products amounted to $788 million, exceeding the average estimate of $777.88 million, representing an 11.9% year-over-year increase [4] - Key product performances included: - Cystic fibrosis franchise: $250 million, up 14.4% year-over-year, exceeding the estimate of $234.18 million [4] - Xtandi: $52 million, a 26.8% increase year-over-year, surpassing the estimate of $49.97 million [4] - Trelegy: $85 million, reflecting a 20.4% year-over-year increase, slightly above the estimate of $84.96 million [4] - Evrysdi: $53 million, a 17.9% increase year-over-year, exceeding the estimate of $51.98 million [4] Stock Performance - Over the past month, Royalty Pharma's shares returned +1.5%, while the Zacks S&P 500 composite increased by +11.3%, indicating underperformance relative to the broader market [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the market in the near term [3]